Evidence map›Paper›PMID 33054324›Full record

ArticleCell transplantation

Preclinical Evaluation of a Single Intravenous Infusion of hUC-MSC (BX-U001) in Rheumatoid Arthritis.

Linan Liu, Henry P Farhoodi, Menglu Han, Guangyang Liu, Jingxia Yu, Lily Nguyen, Brenda Nguyen, Agnes Nguyen, Wenbin Liao, Weian Zhao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Mesodermal Derivatives of Pluripotent Stem Cells Route to Scarless Healing.International journal of molecular sciences · 2023
    Review
  9. Article
  10. Article
  11. Mesenchymal Stem Cell-Based Therapy for Rheumatoid Arthritis.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Linan LiuBaylx, Inc., Irvine, CA, USA.
Henry P FarhoodiSue and Bill Gross Stem Cell Research Center, University of California, Irvine, CA, USA.ORCID 0000-0003-1729-5418
Menglu HanSue and Bill Gross Stem Cell Research Center, University of California, Irvine, CA, USA.
Guangyang LiuDepartment of Surgery, University of California, Irvine, Orange, CA, USA.
Jingxia YuDepartment of Surgery, University of California, Irvine, Orange, CA, USA.
Lily NguyenSue and Bill Gross Stem Cell Research Center, University of California, Irvine, CA, USA.
Brenda NguyenSue and Bill Gross Stem Cell Research Center, University of California, Irvine, CA, USA.
Agnes NguyenSue and Bill Gross Stem Cell Research Center, University of California, Irvine, CA, USA.
Wenbin LiaoBaylx, Inc., Irvine, CA, USA.
Weian ZhaoSue and Bill Gross Stem Cell Research Center, University of California, Irvine, CA, USA.
University of California, Irvine · US

Funding

Training Program in Stem Cell Translational Medicine for Neurological DisordersT32NS082174 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI PETER John DONOVAN, Leslie Michels Thompson · 2013 to 2026
$3.3M
Mechano-Sensing CAR-T Cells for Solid Tumor MetastasesR21CA219225 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI ZHAO, WEIAN · 2017 to 2018
$376k
NCI NIH HHS R21 CA219225NINDS NIH HHS T32 NS082174
6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is an inflammatory disease of the joints, which causes severe pain and excessive systemic circulation of harmful inflammatory cytokines. Current treatments are limited, with some patients not responding well, and some experiencing severe and detrimental side effects. Mesenchymal stem cells (MSC) are cell-based therapeutics being evaluated as potent immunomodulators in RA and may provide relief to patients not responding well to drug-based treatments. We evaluated the safety and efficacy of BX-U001 human umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC) to treat RA, in support of a successful investigational new drug application. A collagen-induced arthritis (CIA) mouse model of RA was established in DBA/1 J mice. Mice from the treatment assessment group were given a tail vein infusion of hUC-MSC 24 days after primary RA induction, while control assessment (CA) group mice were given cell-free carrier solution. All animals were evaluated daily for RA symptoms via clinical scoring, blood was taken periodically for cytokine analysis, and mice were dissected at end point for histological analysis. A linear mixed model was used to compare the rate of change among groups. The clinical scores of TA group were significantly reduced compared with CA group (

Indexed as

AnimalsArthritisArthritis, RheumatoidDisease Models, AnimalFlow CytometryHumansInflammationInfusions, IntravenousInterleukin-6MaleMiceMice, Inbred DBAUmbilical CordInterleukin-6anti-inflammatoryarthritisimmunomodulationimmunotherapyinflammationmesenchymal stem cellrheumatoidumbilical cord

Identifiers

PMID33054324
PMCPMC7784581
OpenAlexW3092698537

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.